125 related articles for article (PubMed ID: 36939075)
1. Factors associated with survival in patients with lymphoma and HIV.
Vargas JC; Marques MO; Pereira J; Braga WMT; Hamerschlak N; Tabacof J; Ferreira PRA; Colleoni GWB; Baiocchi OCG
AIDS; 2023 Jul; 37(8):1217-1226. PubMed ID: 36939075
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.
Schommers P; Gillor D; Hentrich M; Wyen C; Wolf T; Oette M; Zoufaly A; Wasmuth JC; Bogner JR; Müller M; Esser S; Schleicher A; Jensen B; Stoehr A; Behrens G; Schultze A; Siehl J; Thoden J; Taylor N; Hoffmann C
Haematologica; 2018 May; 103(5):857-864. PubMed ID: 29439188
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognostic features of 63 HIV-associated diffuse large B-cell lymphoma: a single-center real-world study in China].
Wang CY; Liu J; Liang XP; Guo BL; Hu RZ; Liu Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):203-208. PubMed ID: 35405777
[No Abstract] [Full Text] [Related]
5. HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
Sharma A; Bajpai J; Raina V; Mohanti BK
Indian J Cancer; 2010; 47(1):35-9. PubMed ID: 20071788
[TBL] [Abstract][Full Text] [Related]
6. Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Silverton A; Gunthel C; Adamski M; Mosunjac M; Nguyen ML
AIDS Res Hum Retroviruses; 2014 Jul; 30(7):665-9. PubMed ID: 24707838
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa.
de Witt P; Maartens DJ; Uldrick TS; Sissolak G
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):66-73. PubMed ID: 23797692
[TBL] [Abstract][Full Text] [Related]
8. Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis.
Kriegsmann K; Klee JS; Hensel M; Buss EC; Kriegsmann M; Cremer M; Ho AD; Egerer G; Wuchter P; Witzens-Harig M
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e581-e587. PubMed ID: 31377211
[TBL] [Abstract][Full Text] [Related]
9. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
10. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
11. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
[TBL] [Abstract][Full Text] [Related]
13. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
[TBL] [Abstract][Full Text] [Related]
14. [Non-Hodgkin lymphomas with systemic presentation in patients with HIV infection. Clinical and prognostic factors in a series evaluated before the introduction of the highly active antiretroviral therapy (HAART)].
Segura Huerta A; López Tendero P; Romera Barroso B; Yuste Izquierdo AL; Gironés Sarrió R; Pérez Fidalgo JA; Gómez Codina J; López Aldeguer J
Rev Clin Esp; 2004 Jun; 204(6):303-7. PubMed ID: 15171891
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
[TBL] [Abstract][Full Text] [Related]
16. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; Del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A;
Br J Haematol; 2020 Mar; 188(6):888-897. PubMed ID: 31782146
[TBL] [Abstract][Full Text] [Related]
17. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
Bower M; Gazzard B; Mandalia S; Newsom-Davis T; Thirlwell C; Dhillon T; Young AM; Powles T; Gaya A; Nelson M; Stebbing J
Ann Intern Med; 2005 Aug; 143(4):265-73. PubMed ID: 16103470
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010.
Gopal S; Martin KE; Richards KL; Eron JJ
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):798-805. PubMed ID: 22011066
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
Galicier L; Fieschi C; Borie R; Meignin V; Daniel MT; Gérard L; Oksenhendler E
Blood; 2007 Oct; 110(8):2846-54. PubMed ID: 17609431
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
